Direct answer: Estradiol patch strengths and schedules are product-specific. FDA labeling lists 0.025, 0.0375, 0.05, 0.075, and 0.1 mg per day for Vivelle-Dot twice weekly; Climara once weekly also has a 0.06 mg-per-day strength. These delivery rates do not create a universal patch-to-pill conversion or a personal dose recommendation.
FDA-labeled strengths by product
| Example US product | Application schedule in its label | Nominal delivery strengths |
|---|---|---|
| Vivelle-Dot | Twice weekly | 0.025, 0.0375, 0.05, 0.075, or 0.1 mg/day |
| Climara | Once weekly | 0.025, 0.0375, 0.05, 0.06, 0.075, or 0.1 mg/day |
The number on a patch is its nominal estradiol delivery per day, not the total amount of estradiol physically contained in the system. Products can differ in size, construction, total drug content, adhesion, and labeled schedule.
Starting doses depend on product and indication
Current FDA labeling does not supply one starting dose for every person or every use. For example, Vivelle-Dot labeling starts moderate-to-severe menopausal vasomotor symptoms at 0.0375 mg/day twice weekly and prevention of postmenopausal osteoporosis at 0.025 mg/day twice weekly. Climara labeling starts the listed uses at 0.025 mg/day once weekly and directs adjustment by clinical response.
Those are product-label summaries, not instructions to start, switch, or titrate without a prescriber. Age, symptoms, uterus status, medical history, indication, other medicines, and risk factors change the decision.
Why there is no universal patch-to-pill conversion
FDA labels do not provide a single oral-estradiol-to-patch conversion table that guarantees equivalent blood levels or clinical effects. Oral and transdermal products use different routes, and exposure can vary between people and products. A numeric conversion found online should not be used to change a prescription.
When switching products, the prescriber should specify the exact brand or generic system, strength, schedule, transition timing, monitoring plan, and whether progestogen is needed for a patient with a uterus.
How to read a patch prescription
- Product: confirm the exact named or generic transdermal system.
- Delivery rate: read the mg/day strength, not just the total package drug content.
- Schedule: distinguish once-weekly from twice-weekly systems.
- Indication: the labeled starting dose can differ by treatment goal.
- Replacement: use the exact product's instructions if a patch falls off or is missed.
Safety context that a chart cannot replace
Systemic estrogen labels carry important contraindications and boxed warnings. They direct use of the lowest effective dose for the shortest duration consistent with treatment goals and individual risks, with periodic reevaluation. A strength chart cannot determine whether systemic estrogen is appropriate or whether another medication is needed.
Frequently asked questions
Is 0.075 mg/day a high estradiol patch dose?
It is toward the upper end of the labeled strength range for the products compared here, but “high” is not a personal safety judgment. Product, indication, response, and risk factors matter.
What is the highest estradiol patch strength?
Vivelle-Dot and Climara labels list 0.1 mg/day as their highest marketed delivery strength.
Is a 0.05 mg patch equal to 1 mg oral estradiol?
No universal FDA-labeled conversion supports that one-to-one claim. Switching routes requires an individualized prescription.
Can estradiol patches be cut?
Do not cut a patch unless the exact product's manufacturer instructions explicitly permit it. Patch construction differs by product.
Primary sources
Evidence review completed August 1, 2026. Check Drugs@FDA for later labeling revisions.